A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD

Dry Age Related Macular Degeneration Clinical Trial

Official title:

A Phase I/IIa, Open-Label, Single-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Advanced Dry Age-related Macular Degeneration(AMD)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01674829
• Other study ID #: CHA CTP 1101
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: September 2012
• Est. completion date: September 2017

Study information

• Verified date: April 2024
• Source: CHABiotech CO., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and tolerability of MA09-hRPE cellular therapy in patients with advanced dry AMD To evaluate the safety of the surgical procedures when used to implant MA09-hRPE cells To assess the number of hRPE cells to be transplanted in future studies To evaluate on an exploratory basis potential efficacy endpoints to be used in future studies of MA09-hRPE cellular therapy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: September 2017
• Est. primary completion date: September 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• Adult male or female over 55 years of age. Patient should be in sufficiently good health to reasonably expect survival for at least four years after treatment
• Clinical findings consistent with advanced dry AMD
• GA defined as attenuation or loss of RPE as observed by biomicroscopy, OCT, and FA.
• No evidence of current or prior choroidal neovascularization in the treated eye
• The visual acuity (BCVA) of the eye to receive the transplant found to be eligible for trial based on study protocol
• Electrophysiological findings consistent with advanced dry AMD.
• Medically suitable to undergo vitrectomy and subretinal injection.
• Medically suitable for general anesthesia or waking sedation, if needed.
• Medically suitable for transplantation of an embryonic stem cell line

Exclusion Criteria:

• Presence of active or inactive CNV in the eye to be treated.
• Presence or history of retinal dystrophy, retinitis pigmentosa, chorioretinitis, central serious choroidopathy, diabetic retinopathy or other retinal vascular or degenerative disease other than ARMD.
• History of optic neuropathy.
• Macular atrophy due to causes other than AMD.
• Presence of glaucomatous optic neuropathy in the study eye, uncontrolled IOP, or use of two or more agents to control IOP (acetazolamide, beta blocker, alpha-1-agonist, prostaglandins, anhydrous carbonic inhibitors)
• Cataract of sufficient severity likely to necessitate surgical extraction within 1 year.
• History of retinal detachment repair in the study eye.
• History of myocardial infarction in previous 12 months.
• History of diabetes mellitus.
• History of cognitive impairments or dementia which may impact the patients ability participate in the informed consent process and to appropriately complete evaluations.
• Any immunodeficiency.
• Any abnormalities in laboratory test result.
• Serologic evidence of infection with Hepatitis B, Hepatitis C, or HIV.
• Current participation in any other clinical trial.
• Participation within previous 6 months in any clinical trial of a drug by ocular or systemic administration.
• Any other sight-threatening ocular disease.
• Ocular lens removal within previous 3 months.
• Ocular surgery in the study eye in the previous 3 months
• If female, pregnancy or lactation.
• Any other medical condition, which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromises patient safety, or interferes with the interpretation of the study results.

Related Conditions & MeSH terms

• Dry Age Related Macular Degeneration
• Macular Degeneration

Intervention

Biological:
• MA09-hRPE
Transplantation of MA09-hRPE cells accoding to the assigned dose group

Locations

Country	Name	City	State
Korea, Republic of	CHA Bundang Medical Center	Seongnam-si	Gyeonggi-do

Sponsors (1)

Lead Sponsor	Collaborator
CHABiotech CO., Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of hESC derived RPE cells	The transplantation of hESC-derived RPE cells MA09-hRPE will be considered safe in the absence of: Any grade 2 (NCI grading system) or greater adverse event related to the cell product; Any evidence that the cells are contaminated with an infectious agent; Any evidence that the cells show tumorigenic potential	12 months
Secondary	exploratory evaluations for potential efficacy endpoints	Secondary endpoints will be evaluated as exploratory evaluations for potential efficacy endpoints.; Change in the mean of BCVA; Autofluorescense photography; Reading speed; Evidence of successful engraftment will consist of: Structural evidence (OCT imaging, fluorescein angiography, slitlamp examination with fundus photography) that cells have been implanted in the correct location; Electroretinographic evidence (mfERG) showing enhanced activity in the implant location	12months